681 related articles for article (PubMed ID: 26090572)
1. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
3. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
[TBL] [Abstract][Full Text] [Related]
4. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
5. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
[TBL] [Abstract][Full Text] [Related]
7. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
8. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA; Giuliano AR; Iversen OE; Bouchard C; Mao C; Mehlsen J; Moreira ED; Ngan Y; Petersen LK; Lazcano-Ponce E; Pitisuttithum P; Restrepo JA; Stuart G; Woelber L; Yang YC; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Chan IS; Chen J; Gesser R; Moeller E; Ritter M; Vuocolo S; Luxembourg A;
N Engl J Med; 2015 Feb; 372(8):711-23. PubMed ID: 25693011
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls.
Iwata S; Murata S; Rong Han S; Wakana A; Sawata M; Tanaka Y
Jpn J Infect Dis; 2017 Jul; 70(4):368-373. PubMed ID: 28003597
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
[TBL] [Abstract][Full Text] [Related]
12. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
13. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.
Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A
Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on the 9-valent HPV vaccine.
Lopalco PL
Drug Des Devel Ther; 2017; 11():35-44. PubMed ID: 28053505
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.
Kosalaraksa P; Mehlsen J; Vesikari T; Forstén A; Helm K; Van Damme P; Joura EA; Ciprero K; Maansson R; Luxembourg A; Sobanjo-ter Meulen A
Pediatr Infect Dis J; 2015 Jun; 34(6):627-34. PubMed ID: 25831420
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the 9-valent HPV vaccine in men.
Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Couillard M; Krajden M; Ouakki M; Murphy D; Trevisan A; Dionne M
Hum Vaccin Immunother; 2014; 10(8):2438-45. PubMed ID: 25424952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
